Home › Acute Lymphoblastic Leukemia › Ohio › Cincinnati
Pag-aaral pangklinika para sa Acute Lymphoblastic Leukemia sa Cincinnati, OH
Isang pag-aaral para sa Acute Lymphoblastic Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Cincinnati. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- at 3 pa
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Nagre-recruitPhase 2
- Oncology Hematology Care, Cincinnati
- Cincinnati Children's Hospital Medical Center, Cincinnati
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Nagre-recruitPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Nagre-recruitPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Nagre-recruitPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Nagre-recruitObservasyonal na pag-aaral
- Children's Hospital Medical Center, Cincinnati
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- Cincinnati Children's Hospital, Cincinnati
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
Nagre-recruitPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Nagre-recruitObservasyonal na pag-aaral
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Nagre-recruitPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Pag-aaral para sa Acute Lymphoblastic Leukemia sa ibang lungsod
- Houston, TX28 pag-aaral
- New York City, NY24 pag-aaral
- Baldwin Park, CA21 pag-aaral
- Seattle, WA21 pag-aaral
- Chicago, IL19 pag-aaral
- Atlanta, GA19 pag-aaral
- Philadelphia, PA16 pag-aaral
- Memphis, TN16 pag-aaral
- Washington, DC16 pag-aaral
- Boston, MA15 pag-aaral
- Los Angeles, CA14 pag-aaral
- Durham, NC13 pag-aaral
Iba pang pag-aaral sa Cincinnati
- Non-Small Cell Lung Cancer35 pag-aaral
- Kanser (lahat ng uri)27 pag-aaral
- Kanser sa Suso25 pag-aaral
- Pagkabigo ng Puso24 pag-aaral
- Colorectal Cancer21 pag-aaral
- Acute Myeloid Leukemia20 pag-aaral
- Metastatic Cancer20 pag-aaral
- Kanser sa Ovary19 pag-aaral
- Kanser sa Baga19 pag-aaral
- Obesity19 pag-aaral
- Kanser sa Prostate18 pag-aaral
- Multiple Myeloma17 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.